European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...
TipRanks on MSN
Milestone’s PSVT nasal spray MAA accepted by EMA
Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...
DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. A detailed picture of the Paroxysmal ...
Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...
According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to ...
Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...
A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...
(MENAFN- GetNews) DelveInsight's "Paroxysmal Supraventricular Tachycardia (PSVT) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Paroxysmal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback